Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRENGTH cardiovascular outcomes study of Epanova added to statin therapy
NL-OMON47312Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of eicosapentaenoic acid + docosahexaenoic acid in hypertriglyceridemia and cardiac morbidity (2 arms), sponsored by AstraZeneca. Started Jun 2015; status: active, not recruiting.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
hypertriglyceridemiacardiac morbidity
Beyond the preview
Go deeper on NL-OMON47312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47312.